Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | DPYD | Q12882 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074433 | 0.83 | LMNA (0.43) | LMNAALDH1A1MAPTCYP19A1TSHR | |
| SCHEMBL5800398 | 0.81 | — | — | |
| SCHEMBL4353311 | 0.81 | DPYD (0.50) | LMNAALDH1A1MAPTCYP19A1TSHR | |
| SCHEMBL161148 | 0.79 | ATAD2 (0.54) | LMNAALDH1A1MAPTCYP19A1TSHR | |
| SCHEMBL5798297 | 0.77 | DPYD (0.46) | LMNAALDH1A1MAPTCYP19A1TSHR | |
| SCHEMBL1916592 | 0.77 | DPYD (0.46) | LMNAALDH1A1MAPTCYP19A1TSHR | |
| SCHEMBL6555485 | 0.77 | DPYD (0.52) | LMNAALDH1A1MAPTCYP19A1TSHR | |
| SCHEMBL44459 | 0.77 | GAA (0.52) | LMNAALDH1A1MAPTCYP19A1TSHR | |
| SCHEMBL4625879 | 0.77 | ALDH1A1 (0.52) | LMNAALDH1A1MAPTCYP19A1TSHR | |
| SCHEMBL2037916 | 0.77 | DPYD (0.46) | LMNAALDH1A1MAPTCYP19A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241503-A | Compound, fluorophore and immunofluorophore as well as preparation methods and application thereof | 辽宁警察学院 | 2025-01-03 | — | — | CN | claimed |
| CN-106632081-A | 5-chloro-6-(chloromethyl) uracil and preparation method thereof | 四川同晟生物医药有限公司 | 2017-05-10 | — | — | CN | claimed |
| WO-2013090873-A1 | A COMPOSITION AND METHOD FOR REDUCING CYANURIC ACID IN RECREATIONAL WATER | HAVILAND PRODUCTS COMPANY (US) | 2013-06-20 | — | — | WO | claimed |
| EP-0898575-B1 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT DR (US) | 2004-12-29 | — | — | EP | claimed |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-10-16 | — | — | US | claimed |
| EP-0898575-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KÖSTER, Hubert (US) | 1999-03-03 | — | — | EP | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
| CN-119241503-A | Compound, fluorophore and immunofluorophore as well as preparation methods and application thereof | 辽宁警察学院 | 2025-01-03 | — | — | CN | disclosed |
| WO-2024030429-A1 | BASE-MODIFIED RIBONUCLEOSIDES AS PRODRUGS AGAINST VIRAL AND BACTERIAL INFECTIONS | THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030429-A1 | BASE-MODIFIED RIBONUCLEOSIDES AS PRODRUGS AGAINST VIRAL AND BACTERIAL INFECTIONS | THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2024-02-08 | — | — | WO | disclosed |
| CN-113024547-B | Bicyclic heterocycles as FGFR4 inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2022-01-13 | — | — | US | disclosed |
| US-4564616-A | Anti-cancer quinazoline derivatives | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-01-14 | — | — | US | disclosed |
| US-4526965-A | Uracil derivatives of thio- and selenourea compounds | POLAROID CORPORATION (US) | 1985-07-02 | — | — | US | disclosed |
| US-4447608-A | ANTITUMOR AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-05-08 | — | — | US | disclosed |
| US-4442290-A | DERIVATIVES OF PYRIMIDINEDIONE | POLAROID CORPORATION (US) | 1984-04-10 | — | — | US | disclosed |
| EP-0071282-A2 | Uracil derivatives and use thereof in photographic products and processes | POLAROID CORPORATION (US) | 1983-02-09 | — | — | EP | disclosed |
| US-4350754-A | FOR PHOTOGRAPHIC FILMS; URACIL DERIVATIVES | POLAROID CORPORATION (US) | 1982-09-21 | — | — | US | disclosed |
| EP-0031237-A1 | Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1981-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | ADAR, RNMT, ATIC | LMNA 2407/4885ALDH1A1 4111/4885MAPT 2388/4885 |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | LMNA 4388/4885ALDH1A1 901/4885MAPT 3789/4885 |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | LMNA 4388/4885ALDH1A1 901/4885MAPT 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.